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Abstract The binding of vascular endothelial growth
factor (VEGF) to VEGF receptor-2 (VEGFR-2) on the
surface of vascular endothelial cells stimulates many steps
in the angiogenic pathway. Inhibition of this interaction is
proving of value in moderating the neovascularization
accompanying age-related macular degeneration and in the
treatment of cancer. Tissue inhibitor of metalloproteinases-
3 (TIMP-3) has been shown to be a natural VEGFR-2
specific antagonist—an activity that is independent of its
ability to inhibit metalloproteinases. In this investigation
we localize this activity to the C-terminal domain of the
TIMP-3 molecule and characterize a short peptide, corre-
sponding to part of this domain, that not only inhibits all
three VEGF-family receptors, but also fibroblast growth
factor and platelet-derived growth factor receptors. This
multiple-receptor inhibition may explain why the peptide
was also seen to be a powerful inhibitor of tumour growth
and also a partial inhibitor of arthritic joint inflammation
in vivo.
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Introduction
Aberrant angiogenesis is now widely accepted as a key
player in a variety of pathological conditions, including
cancer, rheumatoid arthritis and ocular neovascularization.
In the case of malignant tumours, angiogenesis facilitates
tumour growth and metastasis, and in arthritis, the forma-
tion of an inflamed pannus.
Angiogenesis is a complex phenomenon that involves
activation, migration and proliferation of endothelial cells,
smooth muscle cells and pericytes. Various pro-angiogenic
factors are involved in this process including epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF),
platelet derived growth factor (PDGF) and the vascular
endothelial growth factor (VEGF) family—VEGF-A being
considered the predominant effector of angiogenesis. Vas-
cular endothelial cells express the VEGF receptors VEGFR-
1 and VEGFR-2, but only VEGFR-2 appears to mediate the
pro-angiogenic effects of VEGF-A [1].
The growth of new blood vessels also requires break-
down of the surrounding extracellular matrix (ECM). The
principal enzymes involved in this process are the matrix
metalloproteinases (MMPs). Moreover MMPs also release
ECM-bound angiogenic growth factors like VEGF-A,
expose pro-angiogenic integrin binding sites in the ECM,
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and generate pro-migratory ECM derived fragments [2].
The activity of MMPs in tissues is tightly regulated by their
endogenous inhibitors, the tissue inhibitors of metallopro-
teinases (TIMPs), and over-expression of these molecules
in animal models inhibits tumour growth and metastasis
[3]. However a completely novel anti-angiogenic activity
has also been ascribed to one of the four TIMP family
members, TIMP-3. TIMP-3 has been shown to specifically
bind to, and inhibit, VEGFR-2 [4].
The initial aim of this investigation was to begin to map
the site(s) on TIMP-3 involved in its interaction with
VEGFR-2. We show that this involves the C-terminal
domain of the TIMP-3 molecule. Interestingly, a short 16
amino acid peptide sequence, that forms the truncated
C-terminus of a mutant form of TIMP-3, E139X, known to
give rise to the degenerative retinal disease, Sorsby’s
fundus dystrophy [5], also inhibited VEGF receptor-med-
iated signalling by endothelial cells (EC) in vitro. Addi-
tionally, unlike the normal TIMP-3 molecule, the peptide
also moderated their responses to bFGF and PDGF in vitro.
Finally, we show that this TIMP-3 peptide has potent
inhibitory effects on murine tumour angiogenesis and
growth as well as inflammatory arthritis in vivo.
Materials and methods
Proteins/peptides
Peptides corresponding to amino acids: Lys123–Asn138
(KIKSCYYLPCFVTSKN) of the C-terminal domain and
Gly69–Arg84 (GLKLEVNKYQYLLTGR) from the N-ter-
minal domain of TIMP-3 were synthesized by Sheaf
Innovations Ltd., Sheffield, UK, and termed p700 and p323
respectively. Oxidation of the disulfide bond of p700 was
confirmed by mass spectrometry. A 16 amino acid bio-
logically inert control peptide, fibrinopeptide A (FPA) [6]
was purchased from Bachem Distribution Services GmbH,
Hegenheimer, Germany.
Recombinant human TIMP-3 purification
WT-TIMP-3 or N-TIMP-3 cDNA, already bearing a 30 69
His tag and stop codon, were sub-cloned into the pIB/V5-
His-TOPO vector and used to transfect High Five insect
cells (Invitrogen, UK). Clones expressing the highest levels
of recombinant protein were grown in suspension culture
and the conditioned media collected and concentrated by
ultrafiltration. Recombinant proteins were then partially
purified on heparin-agarose columns (Sigma-Aldrich, UK),
eluting with 0.5 M NaCl before a final purification on
Ni2?-NTA-Agarose (Qiagen, UK), eluting with PBS con-
taining 60 mM L-histidine and 0.025 % Brij-35 (pH 7.4).
The purity of the eluted proteins was confirmed by SDS-
PAGE followed by silver-staining and activity confirmed
by reverse-zymography as previously described [7].
Solid phase binding assay
Ninety six-well plates were coated with the extracellular
domain of recombinant human VEGFR-2 fused to the Fc
domain of human IgG1 (rhVEGFR-2, R&D Systems, UK)
by overnight incubation followed by blocking in 5 %
bovine serum albumin/PBS. Recombinant human VEGF165
(R&D Systems, UK), TIMP-3, N-TIMP-3 or peptides
derived from TIMP-3 (p323 or p700) were titrated across
the plates and then biotinylated-VEGF165 added to each
well (2.4 nM final concentration) followed by incubation
for 1 h at room temperature. After washing, the biotinyl-
ated-VEGF165 was detected with avidin-horse-radish per-
oxidase and OPD substrate (Sigma-Aldrich, UK) followed
by spectrophotometry.
Cells
Human dermal microvascular endothelial cells (HuD-
MEC), human umbilical vein endothelial cells (HUVEC),
primary human synovial cells (SC), murine mammary
tumour cells (4T1), and adult human lymphatic endothelial
cells (LEC) were used in this study. HUVEC were main-
tained in Endothelial Cell Growth Medium MV, supple-
mented with 0.4 % (v/v) endothelial cell growth
supplement/heparin (ECGS/H), 2 % (v/v) foetal calf serum
(FCS), 0.1 ng/ml EGF, 1 lg/ml hydrocortisone, and 1 ng/
ml bFGF. HuDMEC and LEC were maintained in Endo-
thelial Cell Growth Medium MV2, supplemented with
0.4 % (v/v) ECGS/H, 5 % (
v/v) FCS, 10 ng/ml EGF and
1 lg/ml hydrocortisone. All the primary human endothelial
cells (passages 2–6 were used) and growth media were
obtained from PromoCell (PromoCell, GmbH, Germany).
4T1 cells (ATCC, LGC Standards, UK) were maintained in
RPMI-1640 medium (Lonza, UK) supplemented with 10 %
(v/v) FCS and 2 mM L-glutamine. SC, isolated from rheu-
matoid arthritis patient biopsies, were a kind gift of Prof A.
G. Wilson, University of Sheffield and cultured in DMEM
(Lonza, UK) supplemented with 10 % (v/v) FCS and 2 mM
L-glutamine. All primary cells or cell lines were maintained
at 37 C in a humidified 5 % CO2 atmosphere.
Cell proliferation assay
Human dermal microvascular endothelial cells were
serum-starved followed by incubating with p700 peptide
for 1 h and then 0.5 nM of VEGF165 for 24 h at 37 C. Cell
proliferation was determined using a BrdU cell prolifera-
tion assay kit (Merck Chemicals Ltd, Nottingham, UK).
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Cell migration assay
The ability of the p700 peptide to inhibit VEGF165-induced
EC migration was determined using a multi-well Boyden
chamber (Neuro Probe, Gaithersburg, USA). Briefly,
serum-starved HuDMEC were treated with p700 for 1 h,
washed and plated in the upper chamber in EBM-2 medium
containing 1 % FCS on an 8 lm fibronectin pre-coated
polycarbonate filter (Neuro Probe, Gaithersburg, USA).
The cells were then left to migrate across the filter for 4.5 h
at 37 C with media containing 0.5 nM VEGF165 in the
presence and absence of inhibitors in the lower chamber.
After the incubation, non-migrating cells on the upper side
of the membrane were scraped off and the migrated cells
were stained with Hema Gurr rapid staining kit (Merck
Chemicals Ltd, Nottingham, UK). Migrated cells were
counted using a light microscope at 1609 magnification in
three random fields per well of three separate wells.
Tube formation assay
Serum-starved HuDMEC were seeded onto MatrigelTM
matrix pre-coated 96 well plates (BD Biosciences, Cowley,
Oxford, UK) at a density of 1 9 104 cells/well in 100 ll
EBM-2 medium. Peptides were then added into each cor-
responding well and incubated for 1 h at 37 C, followed
by stimulated with growth factors, 0.5 nM VEGF165, 1 nM
PDGF-BB or 1.6 nM bFGF, to induce tubule development.
The tubules formed were examined 6 h after stimulation
under a low power (409) light microscope. Images were
captured and analysed by measuring the average tubule
length using ImageJ software (National Institutes of
Health, USA).
Immunoblotting
Transfected HUVEC or HuDMEC pre-treated with 1 lM
test peptides for 1 h, were stimulated with 0.5 nM of
VEGF165 for 2, 5 or 10 min. Cells were lysed and phos-
phorylated proteins detected by western blotting using
phospho-specific antibodies to either VEGFR-2, Erk1/2 or
PI3K (New England BioLabs, UK). Band intensities were
quantified using Bio-Rad Quantity One Analysis software
and normalized using U, un-stimulated control, as 0 %;
and VEGF165, positive control, as 100 % of protein
phosphorylation.
Phosphorylation RTK assays
Serum-deprived HuDMEC were pre-treated with test pep-
tides for 1 h and then stimulated with growth factors
(0.5 nM VEGF165, 1.6 nM bFGF, 1 nM PDGF-BB, 1.6 nM
hepatocyte growth factor, 100 ng/ml EGF or 100 ng/ml
insulin-like growth factor I) for 5 min. Cells were then lysed
and phosphorylated proteins detected using (a) a receptor
tyrosine kinase array (Human Phospho-Receptor Tyrosine
Kinase Array Kit, R&D Systems Ltd.) or (b) sandwich
ELISA (Duo-sets, R&D Systems Ltd.) according to the
manufacturer’s instructions.
Syngeneic mammary tumour model (4T1)
106 4T1 cells were subcutaneously (s.c.) implanted into the
right flank of 5–6 weeks old female BALB/c mice (Charles
River Laboratories, Margate, UK) and grown until the
tumour size reached 100–350 mm3. The tumour sizes were
measured using callipers as described previously [8]. Once
the size of the tumours reached 100–350 mm3, mice were
randomized into control and treatment groups and injected
with either vehicle alone (PBS), 0.025, 0.25 or 2.5 mg/kg
of p700 peptide in PBS, either directly into the tumour (i.t.)
once per week for 2 doses; or intravenously (i.v.) every
other day for 5 doses. At the end of the experiment, animals
were culled and tumours and normal tissues, including lung
and liver, excised and fixed with 10 % neutral buffered
formalin for subsequent analysis, which included general
histology and quantitative measurement of microvascular
density (MVD) and necrosis.
Histological analysis of 4T1 tumours: microvessel
density and tumour necrosis
For MVD measurement, rabbit-anti-mouse CD31 (AbD
Serotech, Kidlington, Oxford, UK) antibody was used and
sections were stained according to standard immunohisto-
logical staining protocols for formalin-fixed tissue sections.
Microvessel density was estimated by measuring the per-
centage of CD31 positive staining in the tumour sections
(15 areas per tumour slide, 7 tumour slides per group) using
AnalySIS^D image analysis software (Olympus, UK). For
the necrotic area inside the tumour, tumour slides were
stained with H&E. Images were measured at 2009 mag-
nification, photographed (15 areas per tumour slide, 7
tumour slides per group) and analysed by AnalySIS^D
image analysis software (Olympus, UK).
Analysis of 4T1 metastases
Normal tissues including lung and liver were stained with
H&E to study tumour metastasis. Total number of metas-
tases per mouse was determined as the number of meta-
static foci on five sections for each animal (n = 7).
Incidence of metastasis was calculated as the percentage of
mice with one or more metastatic nodules in the tissues.
Metastasis severity was scored as follows [9]: minimal
(score 0 = no metastatic nodule), minimal (score 1 = B 4
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metastatic nodules), medium (score 2 = 5–7 metastatic
nodules) or extensive involvement (score 3 = C 8 meta-
static nodules). Each nodule contained C5 nuclei.
In vitro synovial cell invasion assay
Synovial cell invasion was determined using a GFR-
MatrigelTM invasion assay kit (BD Biosciences, USA).
Serum-starved SC were treated with peptide for 1 h, fol-
lowed by stimulation with 100 ng/ml PDGF-BB at 37 C
for 22 h. After incubation, non-invading cells on the upper
side of the chamber were removed and the invaded cells on
the lower side of the membrane were fixed with methanol
and stained with Hema Gurr rapid staining solution
(Merck Chemicals, Ltd.). Cells were counted using a light
microscope at 1609 magnification in 3 random fields per
well of 3 separate wells.
Collagen-induced-arthritis mouse (CIA) model
The CIA mouse was used to evaluate the effect of p700 in
rheumatoid arthritis. Briefly, male DBA-1 mice were sen-
sitized to bovine collagen type II in Freund’s complete
adjuvant, and synchronized with a boost of collagen in
incomplete adjuvant on day 21. Mice were lightly anes-
thetized with halothane. The base of the tail was shaved
and 100 ll collagen II/FCA emulsion (0.1 mg M.tb.,
H37RA, Sigma/100 lL Freund’s incomplete adjuvant,
Difco; Final concentration 100 lg collagen II/100 lL FIA)
was injected intradermally to the left hand side of this site.
21 days after initial sensitization, collagen II was dissolved
in acetic acid as above, emulsified 1:1 in Freund’s
incomplete adjuvant and 100 lL injected into the base of
the tail on the right hand side of the tail base. Mice were
then intravenously treated with vehicle control (PBS) or
p700 peptide (2.5 mg/kg) for 7 doses, i.v. every 2 days into
alternating sides of tail veins from day prior to boost (day
20) to day 35.
The development of the arthritis was assessed by blind
observation of ‘clinical joint score’ (i.e. arthritis scores)
[10]. Mice were individually marked and examined from
the time of the day of boost (day 21). Every inflamed main
digit scored one, inflammation of the front paw scored one,
inflammation of the hind paw scored one, and involvement
of the ankle scored one. Thus a maximal score for each
animal was 22. Animals were also assessed quantitatively
for hind paw inflammation through volumetric measure-
ment by plethysmometry (Ugo Basille Srl, Italy) and
expressed as mL change from day 21 boost baseline. Mice
with arthritis development pre boost were omitted from the
final analysis. Results were also expressed as area under the
curve (AUC) from day 21.
In silico modelling of the TIMP3/VEGFR2 interaction
In order to attempt to assess how TIMP3 and the p700
peptide might bind to and inhibit VEGFR2, in silico
modelling of the interaction was performed. While a
crystal structure for the whole of TIMP-3 is not yet
available, the structures of full length TIMP1 and TIMP2
and the N-domain of TIMP3 have been solved at high
resolution [11–14] enabling a model of the full length
TIMP3 protein to be created using the Phyr2 Server [15]
with high degree of confidence (94 % modeled at [90 %
confidence). This was uploaded to the ZDOCK protein
docking server [16] together with the crystal structure of
the D23 immunoglobulin-homology domains of VEGFR2,
that comprises the VEGFA binding site [17]. From the
predicted structures, the residues present in both molecules
that lie within 4 A˚ of one another were determined using
PyMOL software.
Results
Inhibition of ligand binding to VEGFR-2
We had previously found that HUVEC cells transfected
with cDNA corresponding to full length TIMP3 and a
highly truncated Sorsby’s fundus dystrophy mutated form
of TIMP3, E139X, showed reduced VEGFR2 and Erk1/2
phosphorylation in response to VEGF, whereas the same
cells transfected with the N-terminal domain showed no
reduction in these responses (unpublished observation).
The only difference between the N-terminal domain of
TIMP-3 and the E139X mutant is a sequence of 16 amino
acids (Lys123–Asn138). This implicated a role for this
domain in VEGFR-2 binding. In order to directly test this
hypothesis a peptide corresponding to this sequence
(p700), together with other TIMP-3 derived sequences,
were tested for their ability to inhibit the binding of bio-
tinylated-VEGF165 to the extracellular domain of recom-
binant human VEGFR-2 (Fig. 1). This showed that full
length TIMP-3 and p700, but not N-TIMP-3 or p323, a 16
amino acid peptide sequence from the N-terminal domain,
were able to inhibit the binding of VEGF165 to rhVEGFR-
2. Complete inhibition of B-VEGF165 was not observed for
any of the proteins as increasing inhibitor concentrations
much above those shown led to non-specific binding of
B-VEGF165 to the plate, possibly due to the basicity of all
these peptides.
In order to confirm this effect on the endogenous
VEGFR-2 receptor, a series of in vitro angiogenesis assays
were performed using human dermal microvascular endo-
thelial cells (HuDMEC).
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Inhibition of VEGF165-induced functional responses
of HuDMEC
Cell proliferation and migration
p700 showed a dose responsive inhibition of VEGF165-
induced cell proliferation (to a maximum inhibition of
40 %) and migration (maximum inhibition, 67 %) up to a
concentration of 1 lM (Fig. 2a, b). Concentrations of the
control peptide of 10 lM and above showed some toxicity
to HuDMEC (as determined by propidium iodide stain-
ing—data not shown) so that the optimum dose of peptides
used in subsequent experiments was 1 lM.
Tubule formation
Exposure to 1 lM p700 virtually abolished VEGF165-
induced HuDMEC tube formation ([99 % inhibition)
(Fig. 2c). The binding of VEGF165 to VEGFR-2 has been
shown to be augmented by heparan sulfate proteoglycans
(HSPG) or exogenous heparin that interacts with both
molecules [18, 19]. TIMP-3 also binds to sulfated glycos-
aminoglycans [20], and while this does not seem to be
responsible for its ability to inhibit VEGFR-2 in that
TIMP-3 also inhibits responses to VEGF121 (which lacks a
heparin binding site) [4], there remained a possibility that
p700, being highly basic (calculated pI 9.74), could bind to
heparin, potentially affecting the ability of VEGF165 to
bind to VEGFR-2. However p700 was similarly potent
([97 % inhibition) at inhibiting tubule formation in
response to VEGF121 (Fig. 2d). Addition of the peptide in
the absence of VEGF had no effect on tubule formation,
relative to untreated cells (data not shown).
VEGFR-2-mediated signalling
1lM p700 significantly inhibited VEGF165-induced VEG-
FR-2 phosphorylation by approximately 50 % and this was
comparable to the inhibition by the same concentration of
rhTIMP-3 (45 % inhibition) (Fig. 2e). Similarly, 1 lM
p700 significantly inhibited VEGF165-induced phosphory-
lation of downstream kinase PI3K by approximately 50 %
(Fig. 2f).
Inhibition of other growth factor receptors
A preliminary screen using a phospho-receptor tyrosine
kinase array indicated p700 inhibition of additional VEGF,
FGF and PDGF receptors but not the receptors for EGF,
hepatocyte growth factor (HGFR/Met) or insulin-like
growth factor receptors (data not shown). These data were
then confirmed using a sandwich ELISA to show signifi-
cant inhibition of VEGFR-1, -2 and -3, FGFR-1, -2a, -3
and -4 and PDGFR-a with no inhibition of HGFR or
insulin-like growth factor 1 receptor (Fig. 3a). Additionally
p700 inhibited tubule formation in response to VEGF165,
bFGF and PDGF-BB (Fig. 3b).
Effect of p700 on tumour growth
The effect of p700 on tumour growth in vivo was dem-
onstrated in a syngeneic breast tumour model (4T1 cells) in
BALB/c mice. Tumours in both vehicle control groups
(intravenous and intra-tumour injection sites) grew steadily
and reached the maximum size allowable by day 24, when
the animals were sacrificed. By contrast a weekly intra-
tumour (i.t.) dose of 0.25 mg/kg peptide or intravenous
(i.v.) dose every 2 days of 0.25 mg/kg or above almost
totally abolished tumour growth (Fig. 4a, b).
Effect of p700 on tumour histology
Anti-CD31 staining of the tumour sections revealed a
significant (approximately 50 %) reduction in microvas-
cular density in both treatment groups compared to that
seen in the control groups (Fig. 4c, d). This may, at least in
part, account for the observed inhibition in tumour growth.
While there was an indication of increased necrosis and
decreased metastases in the treated group, this failed to
reach significance.
In vitro effects of p700 on synovial cell invasion
The growth factor receptor inhibitory profile of p700
indicated it may also have an effect on the invasive phe-
notype of rheumatoid arthritis synovial cells, which lack
VEGFR2 [21], but respond to PDGF and fibroblast growth
Fig. 1 The binding of biotinylated-VEGF165 (B-VEGF) to rhVEGFR-
2 following pre-incubation with either unlabelled VEGF165 (VEGF165),
WT-TIMP-3 (WT-T3), N-TIMP-3 (N-T3), p700 peptide (p700) or
p323 peptide (p323) relative to the binding of B-VEGF alone
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factor (FGF). While synovial cells failed to migrate
through MatrigelTM in response to bFGF (data not shown),
they showed marked invasion in response to PDGF-BB and
this response was significantly inhibited (by approximately
40 %) in the presence of p700 (Fig. 5).
Effect of p700 on murine collagen-induced arthritis
In order to test whether the effect of p700 on synovial cell
invasion would translate into a therapeutic effect in vivo,
the peptide was tested in a mouse collagen-induced arthritis
(CIA) model. Injections of 2.5 mg/kg p700 every 2 days
significantly inhibited CIA progression (Fig. 6a, b). Both
the clinical presentation of disease as well as hind paw
inflammation were reduced.
In silico modelling of the TIMP3/VEGFR2 interaction
The top 5 predicted TIMP-3/VEGFR2 interactions from the
ZDOC server were examined. Figure 7a shows the known
structure [17] of VEGFA bound to domains D23 of
VEGFR2 and Fig. 7b, the highest scoring model of TIMP-
3 bound to the same receptor domains, with the p700
sequence highlighted. Figure 7c–f show residues from the
Fig. 2 p700 inhibits VEGF-
mediated responses in
HuDMEC. p700 showed a dose
responsive inhibition of
a VEGF165-induced HuDMEC
proliferation, b cell migration
and (at 1 lM) almost totally
abolished both c VEGF165- and
d VEGF121-induced tubule
formation. Mean ± SEM,
n = 4, *p \ 0.05 compared to
positive control, Mann–Whitney
U test). Similarly p700 inhibited
VEGF165-induced
phosphorylation of eVEGFR-2
itself and f downstream kinase
PI3K (means ± SEM, n = 3.
*p \ 0.05 w.r.t. positive
control, Mann–Whitney U test).
All data were normalized using
U, untreated cells, as 0 % and
VEGF only-treated cells as
100 % activity. In all cases the
control peptide (CP) had no
significant effect
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N-domain, loop 4, loop 6 and the C-terminal tail of TIMP-3
respectively, and the corresponding VEGFR2 residues, that
lie within 4 A˚ of one another, highlighted in space filling
mode using PyMOL.
Discussion
Initially it was assumed that the anti-angiogenic activities
of TIMPs were due to their ability to inhibit MMPs.
However TIMP-2 and TIMP-3 have since been shown to
exhibit anti-angiogenic activities that are independent of
MMP inhibition [4, 22]. For TIMP-2 this appears to be due
to its ability to bind a3b1 integrin [23] whereas for TIMP-3
it is due to its ability to bind to and inhibit VEGFR-2 [4].
The ability of TIMP-3 to inhibit VEGFR-2 mediated
angiogenesis may play a critical role in the eye, regulating
vascularization of the retina [24, 25]. Indeed specific
mutations in TIMP-3 result in the autosomal dominant
degenerative disease of the macula, Sorsby’s fundus
dystrophy (SFD), frequently characterized by abnormal
retinal vascularization [26].
While the ability of TIMPs to inhibit MMPs lies within
their N-terminal domain, a number of activities that are
specific to individual family members, such as pro-MMP
binding, have been shown to reside in the C-terminal
domain [27]. The data presented here indicate that this
domain is also largely responsible for VEGFR-2 inhibition.
This finding supports the observation that full length and
C-terminal domain TIMP-3, but not N-TIMP-3 are able to
inhibit aortic endothelial cell sprouting in mice [24].
Moreover the fact that p700 was able to mimic both the
anti-angiogenic effects of TIMP-3, and its ability to inhibit
VEGF binding to VEGFR-2, strongly implicates this
proximal region of the C-terminus as the region that
interacts with the VEGF binding site of the receptor.
The fact that TIMP-3 and p700 were less potent than
unlabelled VEGF165 in competing with B-VEGF165 for
receptor binding may simply reflect the fact that both the
recombinant VEGFR-2 and VEGF165 are dimers, poten-
tially resulting in a significant avidity effect, whereas
TIMP-3 is monomeric. Indeed it has been observed that
monovalent VEGFR-2 has an approximately 100-fold
lower affinity for VEGF165 than the dimer [28].
TIMP-3 appears to bind VEGFR-2 specifically, with no
inhibition of the closely related VEGFR-1, FGFR1 or
PDGFR-b receptors [4]. In contrast, the p700 sequence also
significantly inhibited the phosphorylation of VEGFR-1,
VEGFR-3, PDGFR-a and FGFR-1, -2, -3 and -4 by their
respective ligands, as well as VEGF-A PDGF-BB and
bFGF-induced tubule formation. In the latter experiment
some inhibition of bFGF-induced tubule formation was
also seen with TIMP-3, which is in keeping with earlier
reports demonstrating TIMP-3 inhibition of both VEGF-A
and FGF-mediated angiogenesis in vitro and in vivo [29].
However a more recent report from the same laboratory
showed that TIMP-3 did not inhibit bFGF or PDGF-BB
induced proliferation of FGFR1 or PDGFR-b-transfected
porcine aortic endothelial cells respectively, or PDGF-BB
induced binding or phosphorylation of PDGFR-b in the
same cells [4]. A likely explanation for this apparent dis-
crepancy is the previously observed synergy between
VEGF and FGF, whereby a significant proportion of the
angiogenic effect of FGF on endothelial cells is dependent
on the activity of autocrine and paracrine VEGF induced
by FGF [30]. Clearly, however, this would not explain the
inhibition of phosphorylation of FGF or PDGF receptors
observed in our studies. Moreover, the fact that p700
potently inhibits PDGF-induced invasion of synovial cells,
which lack VEGF tyrosine kinase receptors [21], confirms
a direct effect on PDGFR.
The pattern of inhibition of p700 for additional tyrosine
kinase receptors is in keeping with their structural
Fig. 3 p700 peptide inhibits phosphorylation of multiple tyrosine
kinase receptors. a p700 peptide significantly inhibited VEGFR-1, -2
and -3, PDGFR-a, FGFR-1, -2a, -3 and -4 phosphorylation in
response to their respective ligands. b p700 inhibited VEGF, bFGF
and PDGF-BB stimulated tubule formation in vitro. Control peptide
(CP), growth factor (GF), WT-TIMP-3 (WT-T3). Means ± SEM,
n = 3. *p \ 0.05 w.r.t positive control (Mann–Whitney U test)
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conservation [31], as all have extracellular domains com-
prising immunoglobulin-homology repeats, with domains 2
and 3 (D23) playing major or exclusive roles in ligand
binding. In contrast EGFR, HGFR or IGF-1R, which were
not inhibited by p700, lack this domain structure. Indeed
the in silico modelling using ZDOC indicated that TIMP-3
potentially occupies the D23 interface in a very similar
manner to the ligand. Closer examination of this model
showed 2 residues found in the p700 sequence, Phe133 and
Val134 potentially in close contact with the ligand binding
site. Although our data, and those recently published by Qi
et al.[32], excluded the amino domain of TIMP-3 in
VEGFR2 inhibition, some potential contact residues were
also found there. This does not necessarily discredit the
model, as it is possible these residues help stabilise the
interaction but are insufficient to allow binding of
N-TIMP-3 alone. However the majority of residues of
TIMP-3 in contact with VEGFR2 in the model lie in the
Fig. 4 p700 reduces the growth
of 4T1 mammary
adenocarcinoma in mice and
inhibits tumour angiogenesis.
Animals were injected with
either PBS (vehicle control) or
PBS containing 0.025, 0.25 or
2.5 mg/kg p700 peptide—either
a directly into the tumour (i.t.)
or b intravenously (i.v.)—at the
times indicated by the arrows,
and tumour size measured using
callipers so that the average
tumour volume could be
calculated. Data are
means ± SEMs, n = 7. At the
end of the procedure, the
differences in mean tumour
volume between vehicle control
and p700 treated groups were
significant (*i.t. route:
p \ 0.0025 and i.v. route:
^0.025 mg/kg treated group,
p \ 0.05; *0.25 mg/kg treated
group, p \ 0.02; ?2.5 mg/kg
treated group, p \ 0.05; Mann–
Whitney U test). c Tumour
vasculature. Tumours from
control animals (U), or p700-
treated (p700), were
immunostained for CD31
(brown) and photographed using
an Olympus light microscope.
Bar 150 lm. N necrotic area.
Microvascular density (MVD)
was then quantified d using
AnalySIS^D image analysis
software. The results show p700
significantly inhibits
microvascular density in both
i.v. and i.t. treatment groups.
Data are means ± SEMs, n = 7
tumours/group. *p \ 0.05 w.r.t.
vehicle control group (Mann–
Whitney U test)
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carboxyl domain, with both loop 6 and the COOH-tail
sequence showing several sites of direct interaction. This is
supported by the fact that peptides corresponding to these
domains are also potent inhibitors of VEGFR2 [32]. While
these authors failed to show inhibition with a 10 amino acid
peptide corresponding to loops 4 and 5, that peptide lacks
some of the residues found in p700 shown in the model to
lie in the ligand binding site. The fact that p700 is highly
promiscuous compared to the natural ligands, or indeed
TIMP-3 itself, is presumably due to the diminutive size of
the p700 peptide potentially abrogating specificity con-
straints of those much larger molecules.
While VEGF-A is considered the major angiogenic
activator for endothelial cells, other growth factors,
including bFGF [30] and PDGF-BB [33], synergize with
VEGF or are directly angiogenic. Moreover angiogenesis is
also dependent on pericytes and smooth muscle cells that
stabilize the new vessels, and these cells respond to other
growth factors, including bFGF and PDGF-BB, rather than
VEGF. The latter growth factors are also potent mitogens
for tumour cells [34]. These molecules may also play
important roles in rheumatoid arthritis with, for example,
bFGF being a potent inducer of osteoclastogenesis [35] and
PDGF-BB, together with transforming growth factor beta,
greatly potentiating fibroblast-like synoviocytes’ response
to inflammatory cytokines [36].
This wider inhibitory profile of p700 may account for
the apparent potency of the molecule in preventing tumour
growth in the 4T1 mouse model and, to a lesser extent, in
modulating arthritis in the CIA mouse model. While there
was no significant decrease in tumour metastasis in the 4T1
model, this is a highly invasive and aggressive tumour and
earlier dosing may have been more effective. The fact that
the efficacy of p700 in the CIA model was less dramatic
than in the 4T1 tumour model is not surprising. Subclinical
disease and angiogenesis already occurs by day 21, and the
boosted model provides a robust immune response. In
addition, the fibroblastic role in arthritic disease occurs in
the later chronic phases of the disease. A more potent
action may have been effected at a higher dose, or with
daily dosing, however resources did not permit these
additional regimes. Angiogenesis plays an important role in
chronic inflammation [37], and its inhibition results in
protection against cartilage erosion [38]. Therefore drugs
targeting angiogenic/growth factor receptors may provide
an additional treatment modality to those targeting the
immune system alone. Interestingly, in the mouse K/BxN
model of RA, only inhibition of VEGFR-1 and not VEG-
FR-2 inhibits disease [39]. VEGFR-1 is also expressed by
monocytes/macrophages and osteoclast precursor cells [40]
and it is possible that angiogenesis and tissue damage in the
rheumatoid joint is largely mediated by infiltration with
these cells which then secrete further angiogenic and
Fig. 5 p700 inhibits PDGF-BB induced synovial cell invasion. U:
untreated cells with (solid bar) or without (open bar) p700; PDGF-
BB: Cells pre-treated with or without p700 and activated with PDGF-
BB. Pooled data are shown as means ± SEM, n = 3. ?p \ 0.05 wrt
U; *p \ 0.05 wrt PDGF alone (Mann–Whitney U test)
Fig. 6 The inhibition of collagen-induced arthritis by p700. Mice
with CIA were dosed with vehicle or p700 at 2.5 mg/kg. a Arthritis
score (p \ 0.001; 2-way ANOVA), and area under curve (inset,
p \ 0.05) relative to vehicle alone. b Hind paw volume (p \ 0.05;
2-way ANOVA), and area under curve (inset, NS). Means ± SEM
(Vehicle n = 8, p700 n = 10—points on AUC graphs are individual
animals)
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catabolic factors, rather than by direct interaction with
VEGFR-2 on endothelial cells.
The majority of anti-angiogenic therapies currently in
clinical practice target the VEGF/VEGFR interaction and
fall into two main categories. The first are antagonists that
target VEGF itself, the major player being bevacizumab
[41], a humanized monoclonal antibody. The second are
small molecule inhibitors that target the tyrosine kinase
domain of these receptors and include sorafenib and suni-
tinib [42]. The former have to be administered intrave-
nously and only target VEGF-A. However VEGF-A may
be replaced as an angiogenic factor by other growth factors
as disease progresses, including VEGF-C and -D, which
can activate VEGFR-2 after proteolytic cleavage [43],
placental growth factor which specifically targets VEGFR-
1 [44], bFGF and PDGF [45]. The tyrosine kinase inhibi-
tors can be taken orally and will also inhibit responses to all
VEGF family members. Current drugs also inhibit several
tyrosine kinase receptor family members in addition to
VEGFR-2, including some intracellular signalling mole-
cules. While this may broaden their activity against other
pro-angiogenic factors it may also increase their off target
effects.
The data described herein not only implicates the proxi-
mal region of the carboxyl-terminal domain of TIMP-3 in
binding and inhibiting VEGFR-2, it also demonstrates the
feasibility of using a single drug to target multiple tyrosine
kinase receptors via their extracellular ligand binding
domain, rather than their tyrosine kinase domain. This may
provide an additional mode of targeting this family of
receptors that potentially combines the benefits of current
anti-angiogenic therapies; having a broader inhibitory pro-
file than antibodies, but without the potential increased
toxicity of small molecule tyrosine kinase inhibitors that can
affect both intracellular signalling molecules as well as
receptor tyrosine kinases. Moreover, understanding the
mechanism of binding of this peptide to these receptors could
pave the way for the rational design of drugs that target very
specific groups of tyrosine kinase receptors.
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